GURUFOCUS.COM » STOCK LIST » Industrials » Conglomerates » Beroni Group Ltd (XNEC:BTG) » Definitions » Loans Receivable

Beroni Group (XNEC:BTG) Loans Receivable : A$0.00 Mil (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Beroni Group Loans Receivable?

Beroni Group's Loans Receivable for the quarter that ended in Jun. 2023 was A$0.00 Mil.


Beroni Group Loans Receivable Historical Data

The historical data trend for Beroni Group's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beroni Group Loans Receivable Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Loans Receivable
Get a 7-Day Free Trial - - - - -

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Beroni Group Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Beroni Group Loans Receivable Related Terms

Thank you for viewing the detailed overview of Beroni Group's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Beroni Group (XNEC:BTG) Business Description

Traded in Other Exchanges
Address
Zhong Bei High Technology Industrial Park, Level 10, Building 11, Xiqing District, Tianjin, CHN, 300380
Beroni Group Ltd is an Australia based company engaged in the sale of smoking control product (NicoBloc), air purifier, healthcare products and supplements, cosmetics and stem-cell therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Its operating segment includes Nicobloc, Fogibloc air purifier, Olansi water filter, Health supplements, Cosmetic products, Viral diagnostic kits, and Technical advisory service. Geographically, it operates in China and Japan. The highest revenue is generated from the Nicobloc segment through the China region.